reports
Neuralstem Reports Year End 2018 Fiscal Results
Neuralstem Reports Year End 2018 Fiscal Results GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, today reported its financial results for the year ended December 31, 2018. Financial Results for the Year Ended December 31, 2018 Cash Position and Liquidity: At December 31, 2018, cash and investments was approximately $5.8 million as compared to approximately $11.7 million for the same period of 2017. The $8.9...
- GlobalData Department
Neuralstem Inc (CUR) - Medical Equipment - Deals and Alliances Profile
Summary Neuralstem Inc (Neuralstem) is a developer of medicines for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peripheral nerve injury, diabetic neuropathy, lysosomal disease, Parkinson’s disease, huntington’s disease and cerebral palsy, among others. It provides drug treatment for depressive disorder, cognitive complication due to diabetes...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.